Table 2.
Substrate-dependent IC50 or Ki values for inhibition of hOCT2 by cimetidine (data from [35] and our laboratories).
| Cimetidine Ki/IC50 (µM) |
Substrate | Substrate concentration (µM) |
Reference |
|---|---|---|---|
| 14 | Amil | 1 | [62] |
| 36 | ASP | 1 | [63] |
| 23 | ASP | 20 | [44] |
| 26 | ASP | 1 | [62] |
| 27 | Crea | 5 | [64] |
| 1380 | Et | 1 | [57] |
| 510 | Met | 10 | [65] |
| 110 | MPP | 0.01 | Unpublished |
| 142 | MPP | 15 | Unpublished |
| 120 | MPP | 0.01 | [58] |
| 70.4 | NBD-MTMA | 10 | Unpublished |
| 70 | TEA | 5 | [17] |
Amil = Amiloride, ASP = 4-(4-(dimethylamino)styryl)-N-methylpyridinium, Crea = Creatinine, Et = ethidium, Met = metformin, MPP = 1-methyl-4-phenylpyridinium, NBD-MTMA = [2-(4-nitro-2,1,3-benzoxadiazol-7-yl)aminoethyl]trimethylammonium, TEA = tetraethylammonium. Bold = molecules highlighted to show for the same probe substrate the comparable IC50 or Ki